Sinovac director reports 90,000-share holding

Q: What does the SINOVAC BIOTECH (SVA) Form 3 for Lo Yuk Lam report?

The Form 3 reports director Lo Yuk Lam’s initial beneficial ownership in SINOVAC BIOTECH. It shows his directly held common shares at the time he became a reporting insider, without indicating any recent trade activity.

Q: How many SINOVAC BIOTECH (SVA) shares does Lo Yuk Lam hold on this Form 3?

Lo Yuk Lam is reported as holding 90,000 common shares of SINOVAC BIOTECH. These are common shares with a par value of $0.001 per share, listed as his position following the reported holdings entry.

Q: Does the SINOVAC BIOTECH (SVA) Form 3 show Lo Yuk Lam buying or selling shares?

The Form 3 does not show a buy or sell transaction. It records his status as a beneficial owner with 90,000 directly held common shares, serving as a baseline disclosure rather than a trading report.

Q: Is Lo Yuk Lam’s ownership in SINOVAC BIOTECH (SVA) direct or indirect?

The filing classifies his 90,000 common shares as direct ownership. The ownership code is listed as “D,” meaning the shares are held directly in his name rather than through an intermediary entity.

Q: What is the purpose of this SINOVAC BIOTECH (SVA) Form 3 filing?

This Form 3 serves as an initial beneficial ownership statement for director Lo Yuk Lam. It establishes his starting share position in SINOVAC BIOTECH for public disclosure when he became subject to insider reporting rules.

SINOVAC BIOTECH LTD director Lo Yuk Lam filed an initial statement of beneficial ownership on Form 3.

Accepted by SEC EDGAR 03/18/2026 - 08:21 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD director Lo Yuk Lam filed an initial statement of beneficial ownership on Form 3. The filing reports direct ownership of 90,000 common shares, par value $0.001 per share. This is a holdings report only and does not reflect any recent share purchase or sale.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider LO YUK LAM

Role Director

Type	Security	Shares	Price	Value
Holding	Common shares, par value $0.001 per share	--	--	--

Holdings: Common shares, par value $0.001 per share — 90,000 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SINOVAC BIOTECH (SVA) Form 3 for Lo Yuk Lam report?

The Form 3 reports director Lo Yuk Lam’s initial beneficial ownership in SINOVAC BIOTECH. It shows his directly held common shares at the time he became a reporting insider, without indicating any recent trade activity.

How many SINOVAC BIOTECH (SVA) shares does Lo Yuk Lam hold on this Form 3?

Lo Yuk Lam is reported as holding 90,000 common shares of SINOVAC BIOTECH. These are common shares with a par value of $0.001 per share, listed as his position following the reported holdings entry.

Does the SINOVAC BIOTECH (SVA) Form 3 show Lo Yuk Lam buying or selling shares?

The Form 3 does not show a buy or sell transaction. It records his status as a beneficial owner with 90,000 directly held common shares, serving as a baseline disclosure rather than a trading report.

Is Lo Yuk Lam’s ownership in SINOVAC BIOTECH (SVA) direct or indirect?

The filing classifies his 90,000 common shares as direct ownership. The ownership code is listed as “D,” meaning the shares are held directly in his name rather than through an intermediary entity.

What is the purpose of this SINOVAC BIOTECH (SVA) Form 3 filing?

This Form 3 serves as an initial beneficial ownership statement for director Lo Yuk Lam. It establishes his starting share position in SINOVAC BIOTECH for public disclosure when he became subject to insider reporting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LO YUK LAM

(Last)

(First)

(Middle)

10/F, 20 BUTE STREET

MONGKOK, KOWLOON

(Street)

HONG KONG

(City)

(State)

(Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	90,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR